We are live on
!
Find out more
PHS
PFM Health Sciences Portfolio holdings
AUM
$1.1B
1-Year Est. Return
57.92%
This Fund
S&P 500
This Quarter
Est. Return
+10.48%
1 Year Est. Return
+57.92%
3 Year Est. Return
+183.93%
5 Year Est. Return
+283%
10 Year Est. Return
+2,507.28%
AUM
$2.76B
AUM Growth
+$143M
(+5.4%)
Cap. Flow
-$59.1M
Cap. Flow
% of AUM
-2.14%
Top 10 Holdings %
Top 10 Hldgs %
30.84%
Holding
95
New
14
Increased
24
Reduced
13
Closed
10
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
PNT
POINT Biopharma Global Inc. Common Stock
PNT
|
+$38.3M |
| 2 |
HCA Healthcare
HCA
|
+$34.9M |
| 3 |
Biogen
BIIB
|
+$29.6M |
| 4 |
Penumbra
PEN
|
+$28.4M |
| 5 |
BioMarin Pharmaceuticals
BMRN
|
+$24.6M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Johnson & Johnson
JNJ
|
+$80.8M |
| 2 |
Pfizer
PFE
|
+$70.4M |
| 3 |
Merck
MRK
|
+$54.6M |
| 4 |
Becton Dickinson
BDX
|
+$32.2M |
| 5 |
Universal Health Services
UHS
|
+$32M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 88.58% |
| 2 | Financials | 0.34% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
76
SOPHiA GENETICS
SOPH
$561M
| $2.31M | 0.08% |
879,913
-886,149
| -50% | -$3.11M |
|
77
Sight Sciences
SGHT
$387M
| $1.45M | 0.05% |
227,692
-548,589
| -71% | -$4.64M |
|
78
Celcuity
CELC
$4.55B
| $1.41M | 0.05% |
+140,426
| New | +$1.33M |
|
79
Zai Lab
ZLAB
$2.35B
| $808K | 0.03% |
+23,612
| New | +$1.01M |
|
|
PRDS
80
DELISTED
Pardes Biosciences, Inc. Common Stock
PRDS
| $528K | 0.02% |
285,170
-516,034
| -64% | -$1.54M |
|
81
Acadia Pharmaceuticals
ACAD
$4.9B
| – | – |
-384,995
| Closed | -$5.42M |
|
82
Baxter International
BAX
$14B
| – | – |
-323,907
| Closed | -$20.8M |
|
83
CALL
BioCryst Pharmaceuticals
BCRX
$2.36B
| – | – |
-550,000
| Closed | -$5.82M |
|
|
84
Becton Dickinson
BDX
$48.8B
| – | – |
-130,697
| Closed | -$32.2M |
|
|
85
Pfizer
PFE
$149B
| – | – |
-1,343,384
| Closed | -$70.4M |
|
|
86
Universal Health Services
UHS
$10.3B
| – | – |
-317,411
| Closed | -$32M |
|
|
CTLT
87
DELISTED
CATALENT, INC.
CTLT
| – | – |
-218,366
| Closed | -$23.4M |
|
|
KRTX
88
CALL
DELISTED
Karuna Therapeutics, Inc. Common Stock
KRTX
| – | – |
-100,000
| Closed | -$12.7M |
|
|
SGEN
89
CALL
DELISTED
Seagen Inc. Common Stock
SGEN
| – | – |
-40,000
| Closed | -$7.08M |
|
|
AERI
90
DELISTED
Aerie Pharmaceuticals
AERI
| – | – |
-699,531
| Closed | -$5.25M |
|
Similar funds
DAM
MAM
DAM
KCM
MIA
YL
SL
PWA
PFM Health Sciences's Q3 2022 Portfolio in Review
As of Q3 2022, PFM Health Sciences held 95 positions worth $2.76B, up 5.4% from $2.62B the previous quarter. Its ten largest holdings account for 31% of the portfolio.
PFM Health Sciences's Q3 2022 filing shows 14 new, 24 increased, 13 reduced and 10 closed positions. Its largest new stake was POINT Biopharma Global Inc. Common Stock: 4,515,216 shares worth $34.9M. The largest sale was Johnson & Johnson, an estimated $80.8M.
By sector, the portfolio is most concentrated in Healthcare at 89% of assets, down from 94% a quarter earlier, followed by Financials.
- PFM Health Sciences's largest Q3 2022 buy was POINT Biopharma Global Inc. Common Stock: 4,515,216 shares worth $34.9M.
- PFM Health Sciences added most to Penumbra in Q3 2022, an estimated $28.4M increase.
- PFM Health Sciences's biggest Q3 2022 reduction was Johnson & Johnson, cutting an estimated $80.8M.
- PFM Health Sciences fully exited Pfizer in Q3 2022, selling an estimated $70.4M.
- PFM Health Sciences's ten largest holdings make up 31% of its $2.76B portfolio in Q3 2022.
- PFM Health Sciences opened 14 new positions and closed 10 in Q3 2022.
- PFM Health Sciences's portfolio value rose 5.4% quarter-over-quarter to $2.76B.
Based on PFM Health Sciences's 13F filing for Q3 2022, filed 14 Nov 2022.